バイオシミラーモノクローナル抗体の世界市場レポート 2024

バイオシミラーモノクローナル抗体の市場規模は、今後数年間で急速に成長すると予想されます。 2028年には8.5%の年間複合成長率（CAGR）で127億9,000万米ドルに成長すると予想されます。次期に予想される成長は、生物学的製剤への支出の増加、バイオシミラーのポートフォリオの継続的な拡大、個別化されたバイオシミラー治療への傾向、およびバイオシミラーに対する社会の関心の高まりによって促進されると予想されます。この期間に予測される主な動向には、バイオシミラーの治療用途の拡大、個別化されたバイオシミラー治療の開発、業界内でのコラボレーションやパートナーシップの増加、バイオシミラー自動注射器などの専用デバイスの登場、バイオベターの改良版の進化などが含まれます。既存の生物学的製剤の。これらの動向は、イノベーションを強調し、バイオシミラーの入手しやすさと用途を拡大しながら、バイオシミラーの情勢を形作ると予想されます。

バイオシミラーモノクローナル抗体市場は、慢性疾患の有病率の上昇により拡大すると予想されています。がん、自己免疫疾患、関節リウマチなどの慢性疾患は、トラスツズマブ、ベバシズマブ、リツキシマブなどのバイオシミラーモノクローナル抗体を使用して治療されます。がんの発生率は増加傾向にあり、国立バイオテクノロジー情報センターの予測では、少なくとも1つの慢性疾患を患う50歳以上の人の数が2050年までに大幅に増加し、2020年の7,152万2,000人から1億4,266万人に達することが示されています。慢性疾患は、バイオシミラーモノクローナル抗体の市場成長を促進すると予想されます。

高齢者人口の増加も、バイオシミラーモノクローナル抗体市場を牽引することになるでしょう。これらの抗体は、重要な治療法への費用対効果の高いアクセスを提供し、慢性疾患と闘う高齢者の治療費の手頃さと生活の質を向上させます。世界保健機関の推計では、高齢者人口が大幅に増加し、2050年までに世界中で21億人の高齢者になると予測されており、この人口統計のヘルスケアニーズに応える上でのバイオシミラーモノクローナル抗体の重要性が示されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のバイオシミラーモノクローナル抗体市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 合成化学物質
• バイオ医薬品
• その他のタイプ
• 世界のバイオシミラーモノクローナル抗体市場、化合物別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• インフリキシマブ
• リツキシマブ
• アブシキシマブ
• トラスツズマブ
• アダリムマブ
• ベバシズマブ
• 世界のバイオシミラーモノクローナル抗体市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 慢性疾患および自己免疫疾患
• 腫瘍学
• その他の用途

第7章 地域および国の分析

• 世界のバイオシミラーモノクローナル抗体市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のバイオシミラーモノクローナル抗体市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミラーモノクローナル抗体市場の競合情勢
• バイオシミラーモノクローナル抗体市場企業プロファイル
  • Pfizer Inc.
  • Novartis AG
  • AbbVie Inc.
  • Coherus BioSciences
  • Biocon Limited

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Biosimilar monoclonal antibodies belong to a subset of biosimilars known for their role in treating conditions like cancer or rheumatoid arthritis. These intricate proteins are integral in the immune system's function, identifying and eliminating foreign substances such as bacteria and viruses.

Within the category of biosimilar monoclonal antibodies, key types include synthetic chemicals, biopharmaceuticals, and others. Biopharmaceuticals, often referred to as biologic medical products, are pharmaceutical drugs derived from biological sources or semi-synthesized compounds. Notable compounds in this category include infliximab, rituximab, abciximab, trastuzumab, adalimumab, and bevacizumab. They find applications across various medical domains including chronic and autoimmune diseases, oncology, and other therapeutic areas. These biosimilar monoclonal antibodies play a crucial role in addressing a wide spectrum of health conditions.

The biosimilar monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides biosimilar monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a biosimilar monoclonal antibodies market share, detailed biosimilar monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar monoclonal antibodies industry. This biosimilar monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilar monoclonal antibodies market size has grown rapidly in recent years. It will grow from $8.04 billion in 2023 to $9.25 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth observed in the historical period can be attributed to several factors. These include the expiration of patents for certain medications, heightened awareness regarding the efficacy and availability of biosimilars, governmental initiatives supporting their development and utilization, increased investments from pharmaceutical companies in this sector, and a growing acceptance of biosimilars among both clinicians and patients. These elements collectively contributed to the growth and adoption of biosimilars during this period.

The biosimilar monoclonal antibodies market size is expected to see rapidly grown in the next few years. It will grow to $12.79 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the upcoming period is expected to be driven by increasing expenditure on biologic medications, the continual expansion of biosimilar portfolios, the trend towards personalized biosimilar therapy, and a growing public interest in biosimilars. Key trends forecasted for this period include the expansion of therapeutic applications for biosimilars, the development of personalized biosimilar treatments, a rise in collaborations and partnerships within the industry, the emergence of specialized devices such as biosimilar autoinjectors, and the evolution of biobetters - improved versions of existing biologic medications. These trends are anticipated to shape the landscape of biosimilars, emphasizing innovation and expanding their accessibility and applications.

The biosimilar monoclonal antibodies market is anticipated to expand due to the rising prevalence of chronic diseases. Chronic conditions like cancer, autoimmune diseases, and rheumatoid arthritis are treated using biosimilar monoclonal antibodies like trastuzumab, bevacizumab, and rituximab. The incidence of cancer is on the rise, with projections from the National Center for Biotechnology Information indicating a significant surge in individuals aged 50 and older with at least one chronic illness by 2050, reaching 142.66 million from 71.522 million in 2020. This anticipated increase in chronic diseases is expected to fuel market growth for biosimilar monoclonal antibodies.

The growing geriatric population is also set to drive the biosimilar monoclonal antibodies market. These antibodies offer cost-effective access to vital therapies, enhancing treatment affordability and quality of life for older adults combating chronic diseases. The World Health Organization's estimates indicate a substantial rise in the elderly population, with projections of 2.1 billion elderly individuals globally by 2050, illustrating the significance of biosimilar monoclonal antibodies in catering to the healthcare needs of this demographic.

Abzena's collaboration with BioXpress Therapeutics in July 2021 aimed to bolster the biosimilar development landscape. This partnership focused on offering an integrated approach encompassing design advice, cell line development, clinical and commercial manufacturing for third-party biosimilar medication manufacturers. By combining their strengths, the collaboration aimed to streamline drug development processes, offering a flexible and innovative strategy from small-scale development to large-scale production in the biosimilars sector.

Innovations in the biosimilar monoclonal antibody market involve the development of biosimilar versions of therapeutic chimeric monoclonal antibodies. For instance, Enzene Biosciences Ltd.'s launch of Cetuximab in May 2021, a biosimilar of the cancer drug Erbitux, aimed to expand treatment options for conditions like metastatic colorectal cancer and head and neck cancer. The Cetuximab biosimilar was manufactured using a Chinese Hamster Ovary (CHO) cell line, resulting in more human-like glycosylation patterns and, reportedly, a reduced incidence of adverse effects observed in clinical studies in India. This innovation broadens therapeutic alternatives and enhances treatment efficacy while addressing adverse reactions associated with certain medications.

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, successfully acquired Viatris Inc.'s biosimilars business, marking a significant strategic move. The acquisition, though the financial details were undisclosed, positions Biocon Biologics closer to patients, customers, and payors, enhancing their direct commercial capabilities and bolstering infrastructure in both advanced markets and several emerging regions.

Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limitied, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.

North America was the largest region in the biosimilar monoclonal antibodies market in 2023. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The biosimilar monoclonal antibodies market consists of sales of Blitzima, Ritemvia, Rituzena, and Truxima. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilar Monoclonal Antibodies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilar monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilar monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilar monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Synthetic Chemicals; Biopharmaceuticals; Other Types
• 2) By Compound: Infliximab; Rituximab; Abciximab; Trastuzumab; Adalimumab; Bevacizumab
• 3) By Application: Chronic & Autoimmune Diseases; Oncology; Other Applications
• Companies Mentioned: Pfizer Inc.; Novartis AG; AbbVie Inc.; Coherus BioSciences; Biocon Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilar Monoclonal Antibodies Market Characteristics

3. Biosimilar Monoclonal Antibodies Market Trends And Strategies

4. Biosimilar Monoclonal Antibodies Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Biosimilar Monoclonal Antibodies Market Size and Growth

• 5.1. Global Biosimilar Monoclonal Antibodies Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Biosimilar Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Biosimilar Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biosimilar Monoclonal Antibodies Market Segmentation

• 6.1. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Synthetic Chemicals
• Biopharmaceuticals
• Other Types
• 6.2. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab
• 6.3. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Chronic & Autoimmune Diseases
• Oncology
• Other Applications

7. Biosimilar Monoclonal Antibodies Market Regional And Country Analysis

• 7.1. Global Biosimilar Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Biosimilar Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biosimilar Monoclonal Antibodies Market

• 8.1. Asia-Pacific Biosimilar Monoclonal Antibodies Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biosimilar Monoclonal Antibodies Market

• 9.1. China Biosimilar Monoclonal Antibodies Market Overview
• 9.2. China Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biosimilar Monoclonal Antibodies Market

• 10.1. India Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biosimilar Monoclonal Antibodies Market

• 11.1. Japan Biosimilar Monoclonal Antibodies Market Overview
• 11.2. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biosimilar Monoclonal Antibodies Market

• 12.1. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biosimilar Monoclonal Antibodies Market

• 13.1. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biosimilar Monoclonal Antibodies Market

• 14.1. South Korea Biosimilar Monoclonal Antibodies Market Overview
• 14.2. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biosimilar Monoclonal Antibodies Market

• 15.1. Western Europe Biosimilar Monoclonal Antibodies Market Overview
• 15.2. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biosimilar Monoclonal Antibodies Market

• 16.1. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biosimilar Monoclonal Antibodies Market

• 17.1. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biosimilar Monoclonal Antibodies Market

• 18.1. France Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biosimilar Monoclonal Antibodies Market

• 19.1. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biosimilar Monoclonal Antibodies Market

• 20.1. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biosimilar Monoclonal Antibodies Market

• 21.1. Eastern Europe Biosimilar Monoclonal Antibodies Market Overview
• 21.2. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biosimilar Monoclonal Antibodies Market

• 22.1. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biosimilar Monoclonal Antibodies Market

• 23.1. North America Biosimilar Monoclonal Antibodies Market Overview
• 23.2. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biosimilar Monoclonal Antibodies Market

• 24.1. USA Biosimilar Monoclonal Antibodies Market Overview
• 24.2. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biosimilar Monoclonal Antibodies Market

• 25.1. Canada Biosimilar Monoclonal Antibodies Market Overview
• 25.2. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biosimilar Monoclonal Antibodies Market

• 26.1. South America Biosimilar Monoclonal Antibodies Market Overview
• 26.2. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biosimilar Monoclonal Antibodies Market

• 27.1. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biosimilar Monoclonal Antibodies Market

• 28.1. Middle East Biosimilar Monoclonal Antibodies Market Overview
• 28.2. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biosimilar Monoclonal Antibodies Market

• 29.1. Africa Biosimilar Monoclonal Antibodies Market Overview
• 29.2. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biosimilar Monoclonal Antibodies Market Competitive Landscape And Company Profiles

• 30.1. Biosimilar Monoclonal Antibodies Market Competitive Landscape
• 30.2. Biosimilar Monoclonal Antibodies Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AbbVie Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Coherus BioSciences
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Biocon Limited
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Biosimilar Monoclonal Antibodies Market Competitive Benchmarking

32. Global Biosimilar Monoclonal Antibodies Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Biosimilar Monoclonal Antibodies Market

34. Biosimilar Monoclonal Antibodies Market Future Outlook and Potential Analysis

• 34.1 Biosimilar Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Biosimilar Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Biosimilar Monoclonal Antibodies Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer